NexImmune Shares Jump 22% Following FDA IND Clearance for NEXI-003

By Denny Jacob

NexImmune Inc. shares jumped 22% to $1.79 in after-hours trading Thursday after the company said it received IND clearance for NEXI-003 from the Food and Drug Administration.

NEXI-003 is being developed for patients with relapsed or refractory human papillomavirus-related cancers, the clinical-stage biotechnology company said.

The Phase 1 trial will enroll patients at multiple clinical sites across the U.S., NexImmune said.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

07-14-22 1637ET